Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Patrick Donnelly | Citigroup | 12 | 8% |
| Dave Windley | Jefferies | 11 | 18% |
| Max Smock | William Blair | 9 | 11% |
| Elizabeth Anderson | Evercore ISI | 8 | 13% |
| Justin Bowers | Deutsche Bank | 8 | 0% |
| Mike Ryskin | Bank of America | 8 | 0% |
| Charles Rhyee | TD Cowen | 7 | 0% |
| Eric Coldwell | Robert W. Baird | 7 | 0% |
| Ann Hynes | Mizuho Securities | 6 | 17% |
| Casey Woodring | JPMorgan | 6 | 0% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Jefferies | 2 | 13 | 15% |
| Citigroup | 1 | 12 | 8% |
| William Blair | 2 | 10 | 10% |
| TD Cowen | 2 |
| 9 |
| 0% |
| Deutsche Bank | 1 | 8 | 0% |
| Evercore ISI | 1 | 8 | 13% |
| Bank of America | 1 | 8 | 0% |
| JPMorgan | 2 | 8 | 0% |
Charles River's first full quarter under new CEO Birgit Girshick delivered Q1 results in line with lowered expectations, with $996M in revenue declining 1.5% organically and non-GAAP EPS falling 12% to $2.06 on anticipated discrete headwinds including CEO transition stock comp and NHP sourcing costs. The DSA demand environment remained constructive with a 1.04x net book-to-bill on $622M in bookings and proposal activity up in the high single digits, though biotech revenue still lagged on the booking-to-revenue time lag. Management reaffirmed FY2026 EPS guidance of $10.80-$11.30 and expects over 500 basis points of operating margin improvement between the first and second halves of the year, driven by KF Cambodia sourcing savings, completed CDMO/Cell Solutions divestiture, and incremental efficiency initiatives.
Demand | Revenue Growth | Margin | Competitive Dynamics | Cost Pressure | Regulation Policy | M&A | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 8 | 3 | 4 | 2 | 1 | 3 | 4 | 4 |
| 2025Q1 | 11 | 8 | 1 | 6 | 2 | 7 | 2 | 2 |
| 2025Q2 | 13 | 8 | 4 | 1 | 2 | 2 | 1 | |
| 2025Q3 | 10 | 4 | 3 | 3 | 4 | 3 | 3 | 1 |
| 2025Q4 | 9 | 3 | 2 | 5 | 3 | |||
| 2026Q1 | 11 | 1 | 3 | 3 | 3 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 8 | 11 | 13 | 10 | 9 | 11 |
| Revenue Growth | 3 | 8 | 8 | 4 | 1 | |
| Margin | 4 | 1 | 4 | 3 | 3 | 3 |
| Competitive Dynamics | 2 | 6 | 1 | 3 | 2 | 3 |
| Cost Pressure | 1 | 2 | 2 | 4 | 5 | 3 |
| Regulation Policy | 3 | 7 | 2 | 3 | ||
| M&A | 4 | 2 | 3 | 3 | 2 | |
| Pricing | 4 | 2 | 1 | 1 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
CRL Charles River Laboratories | 4 | +1.2% | |
| A Agilent Technologies | 8 | +10.0% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |